LUCA Science is a pre-clinical stage biotechnology company that operates in the healthcare sector. They specialize in developing functional mitochondria as therapeutic agents, a novel approach to treating damaged tissues and organs. This innovative method involves isolating proprietary functional mitochondria and using advanced drug delivery and formulation technology to store and deliver them as a biopharmaceutical agent.

Their primary clients are likely to be healthcare providers and patients suffering from diseases related to damaged tissues and organs. The business model revolves around research and development, with the goal of creating effective treatments that can be marketed and sold to healthcare providers.

LUCA Science has gained recognition in the industry, with presentations at prestigious conferences such as the American Heart Society Annual Meeting and the Japan Society of Obstetrics and Gynecology Annual Congress. They have also been selected for the Japanese Startup Support Program “J-Startup” by the Ministry of Economy, Trade and Industry of Japan and named as one of the Top 10 Japanese Emerging Deep Tech Companies by Forbes Japan.

The company has also established partnerships for joint research, such as with Kyowa Kirin, to further their work on mitochondrial disease treatment. This suggests a revenue stream through collaborative research and potential licensing of their technology.

Keywords: Biotechnology, Healthcare, Mitochondria, Therapeutic Agents, Drug Delivery, Formulation Technology, Damaged Tissues and Organs Treatment, Research and Development, Biopharmaceutical Agent, Joint Research.